Elsevier Inc.

SHERPA: Unknown

People

  1. Aghajanian
    Aghajanian
  2. Norton
    Norton
  3. Abu-Rustum
    Abu-Rustum
  4. Moore
    Moore
  5. Sabbatini
    Sabbatini
  6. Seshan
    Seshan

Groups

  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Surgery (6)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  5. Breast Medicine Service (3)
  6. GDMT, Medicine (3)
  7. Gynecologic Medicine Service (3)
  8. Gynecology Disease Management Team (3)
  9. Biostatistics Service (1)
  10. Cell Biology Program Faculty (1)
Search Within
  1. "Richard Barakat"
  2. "David Fennelly"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (1)
Groups
  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Surgery (6)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  5. Breast Medicine Service (3)
  6. GDMT, Medicine (3)

More Groups

People
  1. David Fennelly (6)
  2. Richard Barakat (6)
  3. John Curtin (5)
  4. William Hoskins (5)
  5. David Spriggs (4)
  6. John Lewis (4)

More People

Years
  1. 1999 (1)
  2. 1997 (1)
  3. 1995 (3)
  4. 1994 (1)
Publications
  1. Gynecologic Oncology (4)
  2. European Journal of Cancer (1)
  3. Seminars in Oncology (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer
    Meeting Abstract

    Husain, A.; Sabbatini, P.; Fennelly, D.; Aghajanian, C.; Barakat, R.; Curtin, J.; Venkatraman, E.; Hoskins, W.; Markman, M.
    Gynecologic Oncology (1999)

    Fulltext@MSK | Save
  • Salvage weekly paclitaxel in recurrent ovarian cancer
    Journal Article

    Abu-Rustum, N. R.; Aghajanian, C.; Barakat, R. R.; Fennelly, D.; Shapiro, F.; Spriggs, D.
    Seminars in Oncology (1997)

    Fulltext@MSK | Save
  • Combination cisplatin (P), ifosfamide (I) with mesna, and 5-fluorouracil (F) chemotherapy in advanced or recurrent cervical carcinoma
    Meeting Abstract

    Gibson, L. E.; Schneider, J.; Reichman, B.; Fennelly, D.; Hakes, T.; Barakat, R.; Curtin, J.; Jones, W.; Lewis, J. L. Jr; Norton, L.; more...
    Gynecologic Oncology (1995)

    Fulltext@MSK | Save
  • Escalating-dose Taxol (T) plus high-dose (HD) cyclophosphamide (C) plus G-CSF (G) followed by rapidly sequences courses of HD carboplatin (CBDCA) plus C rescued with peripheral blood progenitor cells (PBP) in patients with stage IIC-IV ovarian cancer (OC)
    Meeting Abstract

    Fennelly, D.; Schneider, J.; Bengala, C.; Barakat, R.; Curtin, J.; Jones, W.; Lewis, J. L. Jr; Spriggs, D.; Hoskins, W.; Norton, L.
    Gynecologic Oncology (1995)

    Fulltext@MSK | Save
  • Phase I study of Taxol administered weekly in patients with persistent ovarian cancer
    Meeting Abstract

    Fennelly, D.; Shapiro, F.; Spriggs, D.; Aghajanian, C.; Francis, P.; Lewis, J. L.; Jones, W.; Curtin, J.; Barakat, R.; Hoskins, W.
    European Journal of Cancer (1995)

    Fulltext@MSK | Save
  • Treatment of advanced ovarian cancer (AOC) with high-dose (HD) carboplatin (C) and escalating-dose taxol (TXL) with cyclophosphamide (CTX)/TXL-primed peripheral blood progenitor cells (PBP) as hematological support (HS): A phase I study
    Meeting Abstract

    Fennelly, D.; Schneider, J.; Hakes, T.; Crown, J.; Bengala, C.; Reich, L.; Moore, M.; Gulati, S.; Shapiro, F.; Barakat, R.; more...
    Gynecologic Oncology (1994)

    Fulltext@MSK | Save